Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 22,706 shares at $15.24 ($355K) on 2023-12-22, disclosed to the SEC on 2023-12-26.
Scheduled sale ($355k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.07 | 2,200 | $33K | 9.3% |
| 2 | $15.24 | 6,529 | $100K | 28.0% |
| 3 | $15.24 | 6,529 | $100K | 28.0% |
| 4 | $16.48 | 3,677 | $61K | 17.1% |
| 5 | $16.48 | 3,677 | $61K | 17.1% |
| 6 | $16.67 | 94 |
| $2K |
| 0.4% |
| Total | $15.63 avg | 22,706 | $355K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |